Sana Biotechnology (SANA) and Mayo Clinic announced a strategic collaboration to advance development of SC451, Sana’s investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. SC451 is designed to allow a single administration of pancreatic islet cells to support long-term glucose control without the need for ongoing insulin therapy or immunosuppression for patients with type 1 diabetes. The collaboration will draw on Mayo Clinic’s multidisciplinary expertise to accelerate the development, validation, and standardization of protocols and processes for SC451, supporting safe, scalable, and consistent delivery across diverse clinical environments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Durable HIP Technology Data De‑Risks Sana Biotechnology’s SC451 Program and Supports Buy Rating
- Sana announces follow-up results from first-in-human study transplanting UP421
- Sana Biotechnology: Advancing T1D and In Vivo CAR-T Programs with 2026 Catalysts and Solid Cash Runway Supporting Buy Rating
- AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks
- Sana Biotechnology: Emerging Clinical Validation and 2026 Pivotal Milestones Underpin Buy Rating